The North America Latent TB Testing Market was valued at $209.3 Million in 2024 and projected to reach to $239.8 Million by 2029, representing a compound annual growth rate of 2.8%. North America's latent TB testing market demonstrates stable growth supported by mature healthcare systems, regulatory compliance requirements, and established clinical protocols.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US represents 90.6% of North America's latent TB testing market at $189.58 million in 2024, driven by robust healthcare infrastructure, mandatory occupational screening programs, and high diagnostic adoption rates across hospitals and clinics.
North America's latent TB testing market is projected to grow from $209.3 million in 2024 to $239.8 million by 2029 at a 2.8% CAGR, reflecting consistent demand from healthcare facilities and occupational health providers.
Established diagnostic capabilities and advanced laboratory networks across North America support widespread adoption of latent TB testing technologies, including interferon-gamma release assays and tuberculin skin tests.
Canada contributes $24.85 million to the regional market, with strong public health initiatives and immigration screening requirements driving consistent demand for latent TB diagnostic solutions.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | HOUSEHOLD CONTACTS WITH PULMONARY TB (Application) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.8% from 2024 to 2029 |
| Largest Segment | IGRA (Test Type) |
| Market Size Base Year (Billions) | ~USD 0.58 (2024) |
| Revenue Forecast (Billions) | ~USD 0.77 (2029) |
| Segments Covered | Test Type, Application, End User |
3 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| US | USD 189.58 Million |
| Canada | USD 24.85 Million |
The North America latent TB testing market was valued at $209.3 million in 2024 and is expected to reach $239.8 million by 2029.
North America's latent TB testing market is growing at a compound annual growth rate (CAGR) of 2.8% from 2024 to 2029.
North America's latent TB testing demand is primarily driven by healthcare workers, immigrants, immunocompromised individuals, and occupational health compliance requirements.
North America's latent TB testing market is dominated by interferon-gamma release assays (IGRAs), with emerging adoption of point-of-care testing solutions.
North America's 2.8% CAGR reflects the region's lower TB incidence, mature diagnostic infrastructure, and established market saturation compared to endemic regions globally.
The study involved major activities in estimating the current market size for the latent TB testing market. Exhaustive secondary research was done to collect information on the latent TB testing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the latent TB testing market.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| QIAGEN | General Manager |
| Revvity | Area Sales Manager |
Both top-down and bottom-up approaches were used to estimate and validate the latent TB testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Latent tuberculosis testing refers to diagnosing the infection by detecting an immune response to Mycobacterium tuberculosis antigens using either the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). These tests help identify dormant tuberculosis infections in individuals without active symptoms.
Full forecast, segment splits, and company analysis for all Latent TB Testing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report